Cargando…

Safety and Efficacy of DPP4 Inhibitor and Basal Insulin in Type 2 Diabetes: An Updated Review and Challenging Clinical Scenarios

The safety and efficacy of dipeptidyl peptidase-4 (DPP4) inhibitors as monotherapy or in combination with other oral antidiabetic agents or basal insulin are well established. DPP4 inhibitors stimulate glucose-dependent insulin secretion and inhibit glucagon production. As monotherapy, they reduce t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gomez-Peralta, Fernando, Abreu, Cristina, Gomez-Rodriguez, Sara, Barranco, Rafael J., Umpierrez, Guillermo E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167285/ https://www.ncbi.nlm.nih.gov/pubmed/30117055 http://dx.doi.org/10.1007/s13300-018-0488-z

Ejemplares similares

Safety and Efficacy of Inpatient Diabetes Management with Non-insulin Agents: an Overview of International Practices
por: Galindo, Rodolfo J., et al.
Publicado: (2022)

Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes
por: Gomez-Peralta, Fernando, et al.
Publicado: (2017)

Erratum to: Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes
por: Gomez-Peralta, Fernando, et al.
Publicado: (2017)

Basal Versus Sliding-Scale Regular Insulin in Hospitalized Patients With Hyperglycemia During Enteral Nutrition Therapy
por: Umpierrez, Guillermo E.
Publicado: (2009)

Geographical clustering and socioeconomic factors associated with hypoglycemic events requiring emergency assistance in Andalusia (Spain)
por: Gomez-Peralta, Fernando, et al.
Publicado: (2021)

Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea
por: Kang, Yu Mi, et al.
Publicado: (2019)

Diabetes Technology Update: Use of Insulin Pumps and Continuous Glucose Monitoring in the Hospital
por: Umpierrez, Guillermo E., et al.
Publicado: (2018)

When basal insulin is not enough: A dose–response relationship between insulin glargine 100 units/mL and glycaemic control
por: Umpierrez, Guillermo E., et al.
Publicado: (2019)

Comparison of Glycemic Variability and Hypoglycemic Events in Hospitalized Older Adults Treated with Basal Insulin plus Vildagliptin and Basal–Bolus Insulin Regimen: A Prospective Randomized Study
por: Batule, Sol, et al.
Publicado: (2022)

Randomized Study of Basal-Bolus Insulin Therapy in the Inpatient Management of Patients With Type 2 Diabetes Undergoing General Surgery (RABBIT 2 Surgery)
por: Umpierrez, Guillermo E., et al.
Publicado: (2011)

DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
por: Razavi, Michael, et al.
Publicado: (2022)

Application of Artificial Intelligence Techniques for the Estimation of Basal Insulin in Patients with Type I Diabetes
por: Guzman Gómez, Guillermo Edinson, et al.
Publicado: (2020)

Cardiovascular protection by DPP-4 inhibitors in preclinical studies: an updated review of molecular mechanisms
por: Zakaria, Esraa M., et al.
Publicado: (2022)

Comparison of Basal-Bolus and Premixed Insulin Regimens in Hospitalized Patients With Type 2 Diabetes
por: Bellido, Virginia, et al.
Publicado: (2015)

Titratable fixed‐ratio combination of basal insulin plus a glucagon‐like peptide‐1 receptor agonist: A novel, simplified alternative to premix insulin for type 2 diabetes
por: Gomez‐Peralta, Fernando, et al.
Publicado: (2021)

Antioxidant Effects of DPP-4 Inhibitors in Early Stages of Experimental Diabetic Retinopathy
por: Ramos, Hugo, et al.
Publicado: (2022)

Establishment of a selective evaluation method for DPP4 inhibitors based on recombinant human DPP8 and DPP9 proteins
por: Liu, Jinglong, et al.
Publicado: (2014)

Clinical Use of DPP-4 Inhibitors
por: Gallwitz, Baptist
Publicado: (2019)

Renoprotective Effects of DPP-4 Inhibitors
por: Kawanami, Daiji, et al.
Publicado: (2021)

ODP173 Control of Alpelisib-Induced Hyperglycemia With DPP4- Inhibitors as add on to Metformin and Insulin
por: Hee, Nicholas Ken Yoong, et al.
Publicado: (2022)

Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy
por: Gomez-Peralta, Fernando, et al.
Publicado: (2019)

Clinical Research on Type 2 Diabetes: A Promising and Multifaceted Landscape
por: Gómez-Peralta, Fernando, et al.
Publicado: (2022)

Randomized Study Comparing a Basal-Bolus With a Basal Plus Correction Insulin Regimen for the Hospital Management of Medical and Surgical Patients With Type 2 Diabetes: Basal Plus Trial
por: Umpierrez, Guillermo E., et al.
Publicado: (2013)

Discovery of Galangin as a Potential DPP-4 Inhibitor That Improves Insulin-Stimulated Skeletal Muscle Glucose Uptake: A Combinational Therapy for Diabetes
por: Kalhotra, Poonam, et al.
Publicado: (2019)

Topical ocular administration of DPP-IV inhibitors: a new approach for treating diabetes-induced retinal neurodegeneration
por: Simó, Rafael, et al.
Publicado: (2023)

Coadministration of DPP-4 inhibitor and insulin therapy does not further reduce the risk of cardiovascular events compared with DPP-4 inhibitor therapy in diabetic foot patients: a nationwide population-based study
por: Lin, Yi-Hsuan, et al.
Publicado: (2018)

A Comparison of Inpatient Cost Per Day in General Surgery Patients with Type 2 Diabetes Treated with Basal-Bolus versus Sliding Scale Insulin Regimens
por: Phillips, Victoria L., et al.
Publicado: (2017)

The Dipeptidyl Peptidase (DPP)-4 Inhibitors for Type 2 Diabetes Mellitus in Challenging Patient Groups
por: Kountz, David
Publicado: (2013)

Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Dpp4+ interstitial progenitor cells contribute to basal and high fat diet-induced adipogenesis
por: Stefkovich, Megan, et al.
Publicado: (2021)

The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence
por: Zhang, Tianli, et al.
Publicado: (2021)

Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?
por: Nasrallah, Sami N., et al.
Publicado: (2012)

Minimum Effective Dose of DPP-4 Inhibitors for Treating Early Stages of Diabetic Retinopathy in an Experimental Model
por: Bogdanov, Patricia, et al.
Publicado: (2022)

Acute myocardial infarction associated to DPP-4 inhibitors
por: Nunes, J P L, et al.
Publicado: (2014)

Use of DPP-4 inhibitors in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2020)

Evaluation of efficacy and safety of DPP-4 inhibitors for Chinese elderly patients with type 2 diabetes mellitus
por: Yu, Dong-Ni, et al.
Publicado: (2020)

To the editor regarding article “Coadministration of DPP-4 inhibitor and insulin therapy does not further reduce the risk of cardiovascular events compared with DPP-4 inhibitor therapy in diabetic foot patients: a nationwide population-based study”
por: Mayer, Florian J., et al.
Publicado: (2018)

2018 Standards of Care Update: Pharmacologic Approaches to Glycemic Management in People With Type 2 Diabetes
por: Neumiller, Joshua J., et al.
Publicado: (2018)

A randomized controlled trial comparing treatment with oral agents and basal insulin in elderly patients with type 2 diabetes in long-term care facilities
por: Pasquel, Francisco J, et al.
Publicado: (2015)

Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor
por: Wang, Aiying, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_l58g8kjqamoplih9qotqmg26nt